INT41789

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1980
Last Reported 1995
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 6
Disease Relevance 4.03
Pain Relevance 2.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Moxd2)
Anatomy Link Frequency
plasma 1
nerve 1
brain 1
head 1
optic 1
Moxd2 (Mus musculus)
Pain Link Frequency Relevance Heat
Dopamine 11 100.00 Very High Very High Very High
c fibre 2 99.46 Very High Very High Very High
noradrenaline 3 97.96 Very High Very High Very High
lidocaine 6 96.64 Very High Very High Very High
substance P 1 94.80 High High
peripheral neuropathy 1 94.56 High High
Neuritis 1 93.42 High High
monoamine 5 93.28 High High
Neuropeptide 1 92.40 High High
Clonidine 2 92.32 High High
Disease Link Frequency Relevance Heat
Mydriatic 4 99.36 Very High Very High Very High
Multiple System Atrophy 1 98.20 Very High Very High Very High
Encephalopathy 1 97.82 Very High Very High Very High
Convulsion 8 97.44 Very High Very High Very High
Quadriplegia 1 97.44 Very High Very High Very High
Toxicity 5 97.28 Very High Very High Very High
Syndrome 4 97.20 Very High Very High Very High
Neuritis 2 96.08 Very High Very High Very High
Peripheral Neuropathy 1 94.56 High High
Optic Neuritis 1 93.42 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The onset of the symptoms usually occurs as early as 15 days to a maximum of 6 months (most within 2 months) after initiation of treatment. 2) Severe optic neuritis with full recovery in 2 months. 3) Peripheral neuropathy usually dose dependent, with different clinical presentations: polyneuritis with sensory, motor, or both deficits, and few cases of tetraplegia. 4) Encephalopathy frequently associated with one of the precedent symptoms, having a favorable outcome (probably resulting in inhibition of dopamine-beta-hydroxylase by disulfiram).
Negative_regulation (inhibition) of dopamine-beta-hydroxylase in optic associated with dopamine, encephalopathy, quadriplegia, optic neuritis, peripheral neuropathy and neuritis
1) Confidence 0.57 Published 1995 Journal Rev Med Interne Section Abstract Doc Link 7871273 Disease Relevance 1.18 Pain Relevance 0.19
An abnormality of C fibres was confirmed by a marked reduction in nerve dopamine-beta-hydroxylase activity.
Negative_regulation (reduction) of dopamine-beta-hydroxylase in nerve associated with c fibre and dopamine
2) Confidence 0.50 Published 1983 Journal Brain Section Abstract Doc Link 6189547 Disease Relevance 0.99 Pain Relevance 0.69
Patients in whom a deficiency of the enzyme dopamine-beta-hydroxylase is present from birth have many features suggestive of the Bradbury-Eggleston syndrome but manifest normal sweating and biochemically have an elevated plasma and urinary dopamine level.
Negative_regulation (deficiency) of dopamine-beta-hydroxylase in plasma associated with dopamine and syndrome
3) Confidence 0.50 Published 1993 Journal Int Angiol Section Abstract Doc Link 8371002 Disease Relevance 1.04 Pain Relevance 0.14
Moreover, the inhibitor of dopamine-beta-hydroxylase, disulfiram, caused significant decrease in brain noradrenaline (NA) and significant increase in brain dopamine (DA) contents.
Negative_regulation (inhibitor) of dopamine-beta-hydroxylase in brain associated with dopamine and noradrenaline
4) Confidence 0.42 Published 1994 Journal Pharmacol. Toxicol. Section Abstract Doc Link 7800657 Disease Relevance 0.49 Pain Relevance 0.75
Both TyA-induced and 5-HT-induced head-twitches were inhibited by dopamine and noradrenaline, while catecholaminergic denervators such as reserpine and 6-hydroxydopamine, and diethyldithiocarbamic acid, a dopamine-beta-hydroxylase inhibitor, increased the TyA response.
Negative_regulation (inhibitor) of dopamine-beta-hydroxylase in head associated with dopamine and noradrenaline
5) Confidence 0.32 Published 1980 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 6245422 Disease Relevance 0 Pain Relevance 0.42
Selective enzymatic blockade with 3-hydroxy-benzyl-hydrazine (NSD-1015; 25 mg/kg, i.p.), a Dopa-decarboxylase enzyme inhibitor, as well as with bis (4-methyl-homopiperazinyl-thiocarbonyl) disulfide (FLA-63; 2.5 mg/kg, i.p.), a dopamine-beta-hydroxylase blocker, prevented the mydriatic effect of MD.
Negative_regulation (blocker) of dopamine-beta-hydroxylase associated with mydriatic and dopamine
6) Confidence 0.19 Published 1982 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 7121613 Disease Relevance 0.33 Pain Relevance 0.31

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox